GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Degree of Financial Leverage

BVAXF (BioVaxys Technology) Degree of Financial Leverage : 1.35 (As of Jul. 2024)


View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). BioVaxys Technology's Degree of Financial Leverage for the quarter that ended in Jul. 2024 was 1.35. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for BioVaxys Technology's Degree of Financial Leverage or its related term are showing as below:

BVAXF's Degree of Financial Leverage is ranked worse than
75.57% of 1441 companies
in the Biotechnology industry
Industry Median: 0.94 vs BVAXF: 1.35

BioVaxys Technology Degree of Financial Leverage Historical Data

The historical data trend for BioVaxys Technology's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Degree of Financial Leverage Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Degree of Financial Leverage
Get a 7-Day Free Trial - 0.57 0.18 -1.36 -0.86

BioVaxys Technology Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.63 -0.86 -1.10 -1.12 1.35

Competitive Comparison of BioVaxys Technology's Degree of Financial Leverage

For the Biotechnology subindustry, BioVaxys Technology's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVaxys Technology's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's Degree of Financial Leverage falls into.



BioVaxys Technology Degree of Financial Leverage Calculation

BioVaxys Technology's Degree of Financial Leverage for the quarter that ended in Jul. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.021 (Jul. 2024) / -0.095 (Jul. 2023) - 1 )/( -2.001 (Jul. 2024) / -4.827 (Jul. 2023) - 1 )
=-0.7789/-0.5855
=1.33***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


BioVaxys Technology  (OTCPK:BVAXF) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


BioVaxys Technology Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVaxys Technology Business Description

Traded in Other Exchanges
Address
146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.